New Mexico Minority-Based Community Clinical Oncology Program

描述(由申请人提供)： 新墨西哥州的190万人口中，拉美裔和美国印第安人的比例是所有州中最高的(42%的拉美裔，10%的美国印第安人)，因此该州的癌症健康差距巨大。新墨西哥州的人均收入只排在第47位，人口相对年轻，贫穷(27%)，没有保险(22%)。近50%的人生活在农村地区，获得医疗保健的机会有限。新墨西哥州肿瘤登记处是NCI SEER计划的创始成员之一，根据该机构的跟踪，新墨西哥州的多种族人口的癌症发病率和死亡率模式截然不同。虽然北部的NM拉美裔主要来自早期的西班牙土地批出家庭，但南部的NM拉美裔更多的是墨西哥后裔。新墨西哥州的部落社区特别多样，有19个普韦布洛人、纳瓦霍民族和3个纳瓦霍人乐队，以及吉卡里拉和马斯杰罗阿帕奇人。在这种丰富的背景下，新墨西哥州少数民族社区临床肿瘤学计划(NM MBCCOP)的目标是通过癌症教育和推广计划来建设社区的临床研究能力，并克服重大的社会经济和文化障碍，以增加NCI赞助的癌症治疗和预防临床试验的机会和收益。自2000年(U10CA86780)成立以来，NM MBCCOP一直勤奋工作，通过合作法律协议、共享治理、单一IRB和综合运营，建立一个全州范围的社区临床试验协作网络(新墨西哥州癌症护理联盟(NMCCA))。102名医生参与者(61名A型和41名B型)覆盖了整个州。NM MBCCOP和NMCCA的主要监管和数据管理职能设在新墨西哥大学癌症中心，还有8个其他组成部分和2个附属社区站点。NMCCA主要负责在社区环境中实施和管理NM MBCCOP。在过去的筹资期间，NM MBCCOP超过了其应计目标，平均达到85.7年度治疗和65.34年度预防/控制应计学分。治疗试验的收益增加了25%。在上一次资助期间，521名患者参加了NM MBCCOP试验，其中319名(61.2%)是少数民族(180名西班牙裔，36名美国印第安人，103名混血、其他少数族裔或未申报)。NM MBCCOP现在准备显著增加总体应计费用，并改进其预防和癌症控制临床试验菜单，以增加预防和控制试验的应计费用。总而言之，NM MBCCOP拥有强大的、运行良好的全州基础设施、成功的应计记录以及对未来增长的战略规划。

Description (provided by applicant): With the highest proportion of Hispanics and American Indians of any State (42% Hispanic, and 10% American Indian), New Mexico's 1.9 million people have tremendous cancer health disparities. Ranking only 47th in per capita income, New Mexico's population is relatively young, poor (27%), and uninsured (22%). Nearly 50% live in rural areas with limited access to healthcare. Tracked by The New Mexico Tumor Registry, a founding member of the NCI SEER Program, New Mexico's multiethnic populations has strikingly different patterns of cancer incidence and mortality. While Northern NM Hispanics are derived primarily from early Spanish land grant families, Southern NM Hispanics are more frequently of Mexican descent. The Tribal communities of New Mexico are particularly diverse, with 19 Pueblos, the Navajo Nation and three Navajo Bands, and the Jicarilla and Mescalero Apaches. In this rich context, the goals of The New Mexico Minority-Based Community Clinical Oncology Program (NM MBCCOP) are to build community capacity for clinical research through cancer education and outreach programs, and, to overcome significant socioeconomic and cultural barriers to increase access and accrual to NCI-sponsored cancer treatment and prevention clinical trials. Funded since 2000 (U10CA86780), the NM MBCCOP has worked diligently to build a build a collaborative statewide community clinical trials network (The New Mexico Cancer Care Alliance (NMCCA)) through cooperating legal agreements with shared governance, a single IRB, and integrated operations. The 102 physician participants (61 types A and 41 type B) cover the entire State. The primary regulatory and data management functions of the NM MBCCOP and the NMCCA are located at The University of New Mexico Cancer Center (UNMCC) with 8 other component and 2 affiliate community sites. The NMCCA is primarily responsible for implementing and managing the NM MBCCOP in community settings. In the past funding period, the NM MBCCOP surpassed its accrual goals, averaging 85.7 annual therapeutic and 65.34 annual prevention/control accrual credits. Therapeutic trial accruals have increased 25%. In the last funding period, 521 patients were accrued to NM MBCCOP trials, 319 (61.2%) of whom were ethnic minorities (180 Hispanic, 36 American Indian, and 103 mixed race, other minority, or undeclared). The NM MBCCOP is now poised to significantly increase overall accrual and to improve its prevention and cancer control clinical trial menu in order to increase accrual to prevention and control trials. In summary, the NM MBCCOP has a strong, well functioning statewide infrastructure, a successful accrual record, and a strategic plan for future growth.